Argenx and Insmed Report Q3 Earnings, Shares Rise Amid Bullish Reports

Insmed (INSM) stock surged 11.1% after beating Q3 expectations, raising its Arikayce sales guidance to $420-$430mln. Argenx (ARGX) shares rose 1.5% after reporting adjusted profit of $5.18 per share on $1.13bln in sales, beating analyst estimates. Both companies are highly rated biotech stocks, with Argenx ranking No. 49 on the IBD 50 list.